Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.

Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF.

Gut. 2007 Oct;56(10):1404-9. Epub 2007 May 15.

2.

Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.

Seksik P, Mary JY, Beaugerie L, Lémann M, Colombel JF, Vernier-Massouille G, Cosnes J.

Inflamm Bowel Dis. 2011 Feb;17(2):565-72. doi: 10.1002/ibd.21330.

PMID:
20848502
3.

Azathioprine induced nodular regenerative hyperplasia in IBD patients.

Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, Coutarel P, Loison P, Jian R, Marteau P.

Gastroenterol Clin Biol. 2005 May;29(5):600-3.

4.

Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.

Musumba CO.

Aliment Pharmacol Ther. 2013 Nov;38(9):1025-37. doi: 10.1111/apt.12490. Epub 2013 Sep 16. Review.

5.

6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.

Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.

Am J Gastroenterol. 2007 Nov;102(11):2495-503. Epub 2007 Sep 25.

PMID:
17894846
6.

Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.

Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C, Göke B, Ochsenkühn T.

Eur J Gastroenterol Hepatol. 2006 May;18(5):553-5.

PMID:
16607155
7.

[Portal vein hypertension during azathioprine therapy in patients with Crohn's disease--a frequent phenomenon?].

Ehmsen L, Marko C, Breidert M.

Dtsch Med Wochenschr. 2008 May;133(18):950-3. doi: 10.1055/s-2008-1075672. German.

PMID:
18431703
8.

Azathioprine induced serious portal hypertension: a case series of three IBD patients and review of the literature.

Dooremont D, Decaestecker J, De Wulf D, Ghillebert G, Van Vlierberghe H, Van Dorpe J, Baert F.

Acta Gastroenterol Belg. 2013 Sep;76(3):342-6. Review.

PMID:
24261031
9.

[Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease].

Schumann M, Preiss JC, Loddenkemper C, Günther U, Somasundaram R, Siegmund B, Zeitz M.

Dtsch Med Wochenschr. 2008 Sep;133(38):1897-900. doi: 10.1055/s-0028-1085573. Epub 2008 Sep 11. German.

PMID:
18788068
10.

The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.

van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.

Inflamm Bowel Dis. 2016 Sep;22(9):2112-20. doi: 10.1097/MIB.0000000000000869.

PMID:
27482972
11.

Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.

De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA.

Scand J Gastroenterol. 2008;43(5):604-8. doi: 10.1080/00365520701800266.

PMID:
18415755
12.

[Nodular regenerative hyperplasia of the liver associated with azathioprine therapy].

Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D.

Gastroenterol Clin Biol. 1991;15(12):968-73. Review. French.

PMID:
1783253
13.

Portal hypertension secondary to azathioprine in myasthenia gravis.

Fonseca V, Havard CW.

Postgrad Med J. 1988 Dec;64(758):950-2.

14.
15.

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.

Fraser AG, Orchard TR, Robinson EM, Jewell DP.

Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32.

16.

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.

Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF.

Gastroenterology. 2003 Aug;125(2):298-303.

PMID:
12891528
17.

Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series.

Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S.

Eur J Gastroenterol Hepatol. 2010 Aug;22(8):1001-5. doi: 10.1097/MEG.0b013e3283360021.

PMID:
20075739
18.

Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease.

Błogowski W, Marlicz W, Smereczyński A, Lawniczak M, Lewosiuk A, Starzyńska T.

Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402. doi: 10.3109/08923973.2010.509727. Epub 2010 Aug 21.

PMID:
20726808
19.

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD.

Gut. 2005 Aug;54(8):1121-5.

20.

Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.

López-Martín C, Chaparro M, Espinosa L, Bejerano A, Maté J, Gisbert JP.

Gastroenterol Hepatol. 2011 Jun-Jul;34(6):385-92. doi: 10.1016/j.gastrohep.2011.03.023. Epub 2011 May 25.

PMID:
21616565

Supplemental Content

Support Center